Denali Therapeutics (DNLI) director granted RSUs and options in new award
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Denali Therapeutics director Peter S. Klein reported equity awards consisting of restricted stock units and stock options. He received 6,408 shares of Common Stock in the form of RSUs, with all RSUs scheduled to vest in full on the earlier of the one-year anniversary of the grant date or the day before the company’s next annual stockholder meeting after the grant date.
He was also granted a stock option covering 19,226 shares of Common Stock at an exercise price of $19.66 per share, with the option vesting on the same schedule as the RSUs. Following these awards, Klein directly owns 33,941 shares of Common Stock and holds the newly granted option for 19,226 underlying shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Klein Peter S
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 19,226 | $0.00 | -- |
| Grant/Award | Common Stock | 6,408 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 19,226 shares (Direct, null);
Common Stock — 33,941 shares (Direct, null)
Footnotes (1)
- Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Includes 6,408 unvested RSUs. 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Key Figures
RSU grant: 6,408 shares
Option grant size: 19,226 shares
Option exercise price: $19.66 per share
+3 more
6 metrics
RSU grant
6,408 shares
Restricted Stock Units granted to director on June 3, 2026
Option grant size
19,226 shares
Stock option covering common shares granted June 3, 2026
Option exercise price
$19.66 per share
Exercise price for 19,226-share stock option award
Shares held after grant
33,941 shares
Total direct common stock holdings following RSU grant
Underlying option shares
19,226 shares
Common shares underlying the new stock option
Option expiration date
June 3, 2036
Expiration of stock option if not exercised
Key Terms
Restricted Stock Unit, RSU, Stock Option (right to buy), exercise price, +1 more
5 terms
Restricted Stock Unit financial
"Each share is represented by a Restricted Stock Unit ("RSU")"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
RSU financial
"Includes 6,408 unvested RSUs."
Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.
Stock Option (right to buy) financial
"Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price": "19.6600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
annual meeting of stockholders financial
"the Issuer's next annual meeting of stockholders occurring after the grant date."
FAQ
What did Denali Therapeutics (DNLI) director Peter S. Klein receive in this Form 4?
Peter S. Klein received equity compensation in the form of 6,408 restricted stock units and a stock option for 19,226 shares. Both awards reflect non-cash grants, increasing his direct equity exposure to Denali Therapeutics through stock-based compensation rather than open-market purchases.
How many Denali Therapeutics (DNLI) RSUs were granted to Peter S. Klein?
He was granted 6,408 RSUs, each representing a right to receive one share of Denali Therapeutics common stock. These units are unvested initially and form part of his overall share ownership, aligning his incentives with long-term company performance upon vesting.
What are the vesting terms for Peter S. Klein’s RSUs at Denali Therapeutics (DNLI)?
All 6,408 RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or the day before Denali Therapeutics’ next annual stockholder meeting. This single cliff vesting schedule ties the award to the director’s upcoming service period.
What stock option grant did Peter S. Klein receive from Denali Therapeutics (DNLI)?
He received a stock option covering 19,226 shares of Denali Therapeutics common stock at an exercise price of $19.66 per share. The option provides the right, but not obligation, to buy shares at that price if it becomes economically attractive.
When do Peter S. Klein’s Denali Therapeutics (DNLI) stock options vest and expire?
One hundred percent of the option shares vest on the earlier of the one-year anniversary of the grant date or the day before the next annual stockholder meeting. The option is scheduled to expire on June 3, 2036, if not exercised earlier according to its terms.